Etripamil structure
|
Common Name | Etripamil | ||
|---|---|---|---|---|
| CAS Number | 1593673-23-4 | Molecular Weight | 452.59 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 593.8±50.0 °C at 760 mmHg | |
| Molecular Formula | C27H36N2O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 312.9±30.1 °C | |
Use of EtripamilEtripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist with a rapid onset of action designed for intranasal administration, used to treat Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells[1][2]. |
| Name | Etripamil |
|---|---|
| Synonym | More Synonyms |
| Description | Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist with a rapid onset of action designed for intranasal administration, used to treat Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells[1][2]. |
|---|---|
| Related Catalog | |
| Target |
L-type calcium channel |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 593.8±50.0 °C at 760 mmHg |
| Molecular Formula | C27H36N2O4 |
| Molecular Weight | 452.59 |
| Flash Point | 312.9±30.1 °C |
| Exact Mass | 452.267517 |
| LogP | 4.14 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.534 |
| InChIKey | VAZNEHLGJGSQEL-MHZLTWQESA-N |
| SMILES | COC(=O)c1cccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)c1 |
| MSP-2017 |
| UNII:S82A18Y42P |
| (-)-MSP-2017 |
| Methyl 3-(2-{[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl](methyl)amino}ethyl)benzoate |
| Benzoic acid, 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]methylamino]ethyl]-, methyl ester |
| Etripamil |